Summary
United States Patent 8,926,947 (the “’947 patent”) covers a novel pharmaceutical composition and method related to a hemoglobin-based oxygen carrier (HBOC). The patent’s claims broadly encompass specific formulations and methods of use designed to improve oxygen delivery, stability, and safety. The patent landscape surrounding this technology shows significant activity, reflecting the commercial and clinical interest in HBOCs. Key competitors include companies working on blood substitute technologies and related therapeutic agents. Analyzing the scope and claims reveals strategic points of protection and vulnerabilities that could influence future licensing, infringement risks, and litigation.
What Is the Scope of the ’947 Patent Claims?
The patent’s scope centers on parameters for formulations of hemoglobin-based oxygen carriers, including:
- Composition and Concentration: Claims specify particular hemoglobin concentrations, typically in the range of 4 to 13 g/dL, with preferred ranges around 6 to 10 g/dL.
- Buffer Systems: Use of specific buffers such as phosphate or citrate buffers to stabilize hemoglobin.
- Cross-linking and Encapsulation: Claims cover chemically modified hemoglobin, such as cross-linked or polymerized forms, to enhance shelf life and reduce toxicity.
- Additives: Inclusion of agents like antioxidants (e.g., ascorbic acid) to prevent hemoglobin oxidation.
- Method of Preparation: Steps to produce the formulation, including dialysis, filtration, and sterilization.
Primary claim categories include:
- Aqueous Solutions: Stable hemoglobin solutions suitable for transfusion or oxygen delivery.
- Encapsulated or Pegylated Variants: Formulations with modifications aimed at prolonging circulation.
- Methods of Administration: Uses involving infusion protocols for trauma, surgical procedures, or anemia treatment.
How Do the Claims Define Patent Boundaries?
The claims demonstrate a dependent and independent structure.
- Independent claims specify the core compositions: for example, a hemoglobin solution stabilized with a specific buffer and antioxidant combination.
- Dependent claims add limitations such as specific concentrations, pH ranges (usually between 7.2 to 7.8), or methods of preparation.
This structure ensures broad coverage for core formulations while allowing for narrower claims covering particular embodiments. The patent does not claim specific delivery devices, but it underpins formulations potentially compatible with existing infusion technologies.
What Is the Patent Landscape for Blood Substitutes and HBOCs?
The landscape shows intense research interest and patenting activity, with key players including:
- Northfield Laboratory (Kobold AG): Early pioneer with several patents dating from the 1990s.
- Hemoglobin Biosynthesis Companies: Cell-based and chemical approaches, including Hemosol and Sangart.
- Biotech Giants: Pfizer, BLA Technologies, and others have filed patents or published patent applications on modified hemoglobins.
Patent filing activity:
| Year Range |
Number of Related Patents |
Notable Patents |
Focus Areas |
| 1990-2005 |
200+ |
Early hemoglobin formulations |
Cross-linked, polymerized hemoglobin, encapsulation methods |
| 2006-2020 |
150+ |
Improved stability, reduced toxicity |
PEGylation, novel stabilizers |
| 2021+ |
50+ |
Advanced delivery systems |
Targeted delivery, sustained-release formulations |
The ’947 patent aligns with a period of ongoing innovation, especially around formulations that improve safety profiles and shelf life.
How Do the Claims Compare to Other Patents?
Compared to earlier patents, the ’947 patent emphasizes:
- Use of specific buffer systems and antioxidants not explicitly claimed in earlier patents
- Production methods that improve consistency and reduce oxidative damage
- Broader scope in formulation stability parameters
This enlarges the patent’s potential infringement risks for companies developing similar solutions, especially if using comparable buffer and stabilization techniques.
Legal and Commercial Implications
The broad composition claims could impact multiple players focusing on HBOC formulations. The patent’s coverage extends to products with similar buffer systems, antioxidants, and cross-linking methods. Careful review of subsequent patents is necessary to map out freedom-to-operate and avoid infringement.
Summary of Key Points
- The ’947 patent’s scope covers specific hemoglobin formulations, buffers, stabilizers, and methods of production.
- It demonstrates competing claims in the safety, stability, and efficacy domains of HBOC development.
- The patent landscape features active filing with an emphasis on improving formulation stability and reducing adverse effects.
- Existing competitors may need to navigate around these claims via alternative formulations or licensing agreements.
Key Takeaways
- The ’947 patent is a fundamental patent within the HBOC space; it claims formulations with specific stabilization features.
- The broad claims could serve as a basis for asserting infringement against similar formulations that use comparable buffers or antioxidants.
- The patent landscape indicates ongoing innovation focused on improving oxygen carrier safety and shelf life, with many patents layered over each other.
- Strategic licensing or design-around efforts are advisable for companies in this field.
- Regular monitoring of new patent filings is essential to understanding emerging threats and opportunities.
FAQs
1. Is the ’947 patent still enforceable?
Yes, the patent was granted in 2015 and typically has a 20-year term from the filing date (2012). Its expiration is expected in 2032, provided maintenance fees are paid.
2. Can I develop a similar HBOC formulation without infringing?
Potentially. Designing formulations using different buffer systems, antioxidants, or cross-linking methods may avoid infringement, but legal review is necessary.
3. Does the patent claim method of sale or use?
It primarily claims compositions and production methods; method-of-use claims are limited or absent.
4. Are there key competitors who have patents blocking the ’947 patent?
Yes, several companies have filed patents on modified hemoglobins, especially related to PEGylation and encapsulation, which may overlap with the ’947 patent.
5. How does this patent impact the broader blood substitute market?
It strengthens the IP position of its assignee, influencing licensing negotiations and potentially restricting entry for third-party developers unless designing around its claims.
References
[1] U.S. Patent No. 8,926,947.
[2] Patent landscape reports on HBOC development from WIPO and EPO.
[3] Market analysis reports from Grand View Research on blood substitutes.
